PWMG
ARQT icon

Prestige Wealth Management Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Prestige Wealth Management Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$5.89K – 1105
2026
Q1 		$5.89K Buy
250
+60
+32% +$1.53K ﹤0.01% 527
2025
Q4 		$5.52K Buy
+190
New +$4.86K ﹤0.01% 555

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Prestige Wealth Management Group's ARQT Position: Q2 2026 in Review

Prestige Wealth Management Group sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 250 shares — an estimated $5.89K sold.

Prestige Wealth Management Group first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $5.89K in Q1 2026. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Prestige Wealth Management Group reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Prestige Wealth Management Group sold 250 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.89K.
  • Prestige Wealth Management Group first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Prestige Wealth Management Group's Arcutis Biotherapeutics position peaked at $5.89K in Q1 2026.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.